270 results
Page 5 of 14
8-K
w0r f9khedoyh8c6
2 Aug 21
Results of Operations and Financial Condition
4:11pm
8-K
EX-99.1
9c67ljs7p yxiz
9 Jul 21
Vaxart Announces Exclusive Worldwide License Agreement with Altesa Biosciences for its Vapendavir Antiviral Asset
4:02pm
8-K
2minyjv yuf7p
3 May 21
Other Events
1:23pm
8-K
EX-99.1
7kgb zx3x6t9fnz3h
23 Apr 21
Vaxart Appoints David Wheadon, M.D., to its Board of Directors
4:00pm
8-K
ukfvc x2uvfp
23 Apr 21
Vaxart Appoints David Wheadon, M.D., to its Board of Directors
4:00pm
8-K
EX-99.1
xfg80rd3
25 Feb 21
Vaxart Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results
4:04pm
8-K
8r4r3rv2gw5f8r4ux656
3 Feb 21
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
8:36am
8-K
EX-99.1
p3jvrg2mmzb44orjm
3 Feb 21
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
8:36am
8-K
EX-99.1
j9a5vam8 h9
12 Nov 20
Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update
4:03pm
8-K
hbu5vb
14 Oct 20
Entry into a Material Definitive Agreement
6:04am
8-K
EX-1.1
33j7o06bt6
14 Oct 20
Entry into a Material Definitive Agreement
6:04am
424B5
o2p25v
13 Oct 20
Prospectus supplement for primary offering
5:27pm